肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展

doi:10.12092/j.issn.1009-2501.2022.05.010

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (5): 562-574.doi: 10.12092/j.issn.1009-2501.2022.05.010

肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展

施经斌1,2，熊阳1,2

1浙江中医药大学药学院，杭州 311402，浙江；2浙江中医药大学中医药科学院，杭州 310053，浙江

收稿日期:2022-04-12 修回日期:2022-05-13 出版日期:2022-05-26 发布日期:2022-06-06
通讯作者: 熊阳，女，教授，博士生导师，研究方向：药物新剂型与新技术研究。 E-mail: xyxnb@126.com
作者简介:施经斌，男，硕士研究生，研究方向：药物新剂型与新技术研究。 E-mail: 1343274877@qq.com
基金资助:
国家自然科学基金（82174095）；浙江省自然科学基金重点项目（LZ22H290001）；浙江省医药卫生科技项目（2021KY813）

Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis

SHI Jingbin1,2, XIONG Yang1,2

1School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 311402, Zhejiang, China; 2Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China

Received:2022-04-12 Revised:2022-05-13 Online:2022-05-26 Published:2022-06-06

摘要/Abstract

摘要： 乳腺癌是一种侵袭性强、转移性强、复发率高的恶性肿瘤，能够通过多种途径实现乳腺癌细胞向其他组织的转移。肿瘤与其他细胞相互作用形成的肿瘤微环境为乳腺癌细胞的转移提供条件。本文综述了近年来肿瘤微环境对乳腺癌细胞转移的作用及机制，包括脂肪细胞、成纤维细胞、神经内分泌细胞、免疫和炎症细胞、血液和淋巴管网络及细胞外基质，并讨论如何为预防乳腺癌转移提供治疗方案。

关键词: 肿瘤微环境, 乳腺癌, 转移, 侵袭, 预防治疗

Abstract: Breast cancer is a malignant tumor with strong invasiveness, strong metastasis and high recurrence rate. Breast cancer cells can be transferred to different tissues in a variety of ways. Breast cancer cells can spread because of the tumor microenvironment created by tumor interaction with surrounding cells. This review examines the role and mechanisms of the tumor microenvironment in breast cancer cell metastasis in recent years, including adipocytes, fibroblasts, neuroendocrine cells, immune and inflammatory cells, blood and lymphatic network, and extracellular matrix, as well as how to treat breast cancer metastasis.

Key words: tumor microenvironment, breast cancer, metastasis, invasion, preventive treatment

中图分类号:

R737.9

施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.

SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.

参考文献 17

[1]	Rybinska, I., Mangano, N., Tagliabue, E., et al. Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences[J]. International Journal of Molecular Sciences, 2021, 22(7): 3775.
[2]	Chinese Preventive Medicine Association. Female breast cancer screening guideline of China(T/CPMA 014-2020)[S]. CHIN J CANCER PREV TREAT(中华肿瘤防治杂志), 2021, 28(1): 9-18.
[3]	Sung, H., Ferlay, J., Siegel, R. L., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[4]	Bergers, G. and Fendt, S.M. The metabolism of cancer cells during metastasis[J]. Nat Rev Cancer, 2021, 21 (3), 162-180.
[5]	Liu, Q., Zhang, H., Jiang, X., et al. Factors involved in cancer metastasis: a better understanding to "seed and soil" hypothesis[J]. Mol Cancer, 2017, 16(1): 176.
[6]	Wang, M., Zhao, J., Zhang, L., et al. Role of tumor microenvironment in tumorigenesis[J]. J Cancer, 2017, 8(5): 761-773.
[7]	Picon-Ruiz, M., Morata-Tarifa, C., Valle-Goffin, J. J., et al. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention[J]. CA Cancer J Clin, 2017, 67(5): 378-397.
[8]	Li S. J., Wei X. H., He J. Y., et al. Tumor-associated Adipose Tissue Microenvironment Supports Tumor Progression[J]. Cancer Res Prev Treat(中国防治研究), 2018, 45(4): 242-246.
[9]	Zhao, C., Wu, M., Zeng, N., et al. Cancer-associated adipocytes: emerging supporters in breast cancer[J]. J Exp Clin Cancer Res, 2020, 39(1): 156.
[10]	Juarez-Cruz, J.C. et al. Leptin induces cell migration and invasion in a FAK-Src-dependent manner in breast cancer cells[J]. Endocr Connect, 2019, 8(11): 1539-1552.
[11]	Colditz, G.A. and Peterson, L.L. Obesity and Cancer: Evidence, Impact, and Future Directions[J]. Clin Chem, 2018, 64(1): 154-162.
[12]	Acheva, A., K?rki, T., Schaible, N., et al. Adipokine Leptin Co-operates With Mechanosensitive Ca2+-Channels and Triggers Actomyosin-Mediated Motility of Breast Epithelial Cells[J]. Front Cell Dev Biol, 2020, 8: 607038.
[13]	Wei, L., Li, K., Pang, X., et al. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2[J]. J Exp Clin Cancer Res, 2016, 35(1): 166.
[14]	Rios Garcia, M., Steinbauer, B., Srivastava, K., M. et al. Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence[J]. Cell Metab, 2017, 26(6): 842-855 e5.
[15]	Li, S. J., Wei, X. H., Zhan, X. M., et al. Adipocyte-Derived Leptin Promotes PAI-1 -Mediated Breast Cancer Metastasis in a STAT3/miR-34a Dependent Manner[J]. Cancers (Basel), 2020, 12(12).
[16]	He, J. Y., Wei, X. H., Li, S. J., et al. Adipocyte-derived IL-6 and leptin promote breast Cancer metastasis via upregulation of Lysyl Hydroxylase-2 expression[J]. Cell Commun Signal, 2018, 16(1): 100.
[17]	Cao, H., Huang, Y., Wang, L., et al. Leptin promotes migration and invasion of breast cancer cells by stimulating IL-8 production in M2 macrophages[J]. Oncotarget, 2017, 7(40): 65441–65453.

肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展

Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 17

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[7]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[8]	王艳, 张金辉, 赵永辰, 刘宏祥, 刘亚维, 苗欢欢, 杨信才. 红杉黄酮通过下调PI3K/AKT信号通路抑制胃癌细胞增殖侵袭等干细胞特性[J]. 中国临床药理学与治疗学, 2023, 28(5): 508-513.
[9]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[10]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[11]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[12]	刘佳佳, 高岩, 张业慧, 武静. CRABP2在肿瘤发生发展中的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 86-92.
[13]	武帅, 杨君, 郑云. 乳腺癌中具有双重功能的miRNA[J]. 中国临床药理学与治疗学, 2022, 27(7): 814-821.
[14]	眭玉霞, 庄捷, 庄敏, 黄桂. Delicaflavone通过PI3K/AKT/mTOR通路调控上皮-间质转化抑制吉非替尼耐药肺癌PC-9/GR细胞迁移和侵袭[J]. 中国临床药理学与治疗学, 2022, 27(6): 614-621.
[15]	董伟, 黄小英, 谢冰斌, 汤喜兰, 李洪铭, 邱雨美, 赵国巍, 梁新丽. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3): 260-266.